Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01015118 · ClinicalTrials.gov registry record · Phase 3
LUME-Ovar 1: Nintedanib (BIBF 1120) or Placebo in Combination With Paclitaxel and Carboplatin in First Line Treatment of Ovarian Cancer
A Phase 3 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,366
- Enrollment target
NCT01015118 is a Phase 3 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 1,366 participants.
The verdict
NCT01015118, a Phase 3 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,366 participants
- Enrollment target
Study Summary
The trial will be performed to evaluate if BIBF 1120 in combination with paclitaxel and carboplatin is more effective than placebo in combination with paclitaxel and carboplatin in first-line treatment of patients with advanced ovarian cancer. Safety information about BIBF1120/paclitaxel/carboplatin will be obtained.
Interventions
- DRUG Carboplatin
- DRUG Placebo
- DRUG Paclitaxel
- DRUG BIBF 1120
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,366 participants |
| Start Date | 2009-11-17 |
| Est. Completion | 2016-09-15 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01015118
The ClinicalTrials.gov registry entry for NCT01015118 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,366 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Carboplatin is the first listed.
NCT01015118 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01015118 about?
NCT01015118 is a clinical study titled "LUME-Ovar 1: Nintedanib (BIBF 1120) or Placebo in Combination With Paclitaxel and Carboplatin in First Line Treatment of Ovarian Cancer". The trial will be performed to evaluate if BIBF 1120 in combination with paclitaxel and carboplatin is more effective than placebo in combination with paclitaxel and carboplatin in first-line treatment of patients with advanced ovarian cancer. Safety information about BIBF1120/paclitaxel/carboplatin...
What is the current status of trial NCT01015118?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,366 participants. The study started on 2009-11-17. Estimated completion is 2016-09-15.
What interventions are being tested in trial NCT01015118?
The interventions under investigation include: Carboplatin (DRUG), Placebo (DRUG), Paclitaxel (DRUG), BIBF 1120 (DRUG).
Who is sponsoring clinical trial NCT01015118?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.